Evolution step-up growth trajectory upward trajectory
Pharma

How biosimilar developers are embracing next phase of US market

Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
Large layoffs of employees Wooden figures of people going to the exit

Novartis dismisses 322 more staffers based out of US headquarters

Jul 7, 2026 11:41am
arrow miss target fail attempt try

BMS details Krazati confirmatory fail in colorectal cancer

Jul 7, 2026 10:46am
Magnifying glass with pills on blue

Regulatory tracker: AbbVie, Genmab's bispecific wins EU expansion

Jul 7, 2026 10:15am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

Tanabe to sell manufacturing unit, rights to 17 meds to Towa

Jul 7, 2026 8:54am
A chessboard with blocks that read MA

Vertex to pay $10B for Crinetics in its largest-ever deal

Jul 7, 2026 8:08am
More News

AI care partner Heidi touts positive side effects in campaign

Jul 7, 2026 6:00am

Skin quality driving widespread quality-of-life issues: survey

Jul 7, 2026 4:47am

Vertex gains FDA expansion of Casgevy to those ages 2 and older

Jul 6, 2026 11:30am

The Oral GLP-1 Tracker: $71M US sales modeled for Foundayo debut

Jul 6, 2026 9:38am